Glioblastoma, the most common, and lethal form of brain cancer made headlines recently due to Senator John McCain’s diagnosis and subsequent death from this aggressive disease. Just one year after being diagnosed with glioblastoma, Senator McCain passed away on August 25th, 2018 at 81.
Each year, 8.2 of every 100,000 people in the U.S. are diagnosed with primary malignant brain tumors.
“Currently, 29.5 of every 100,000 people in the U.S. have primary malignant brain tumors,” said William Fisher, Chairman of the Board of Diverse Biotech, an innovative, clinical-stage biopharmaceutical research company, committed to discovering and developing novel therapeutics from its proprietary cannabinoid product platform.
The median survival time for patients diagnosed with glioblastoma brain cancer, who have surgery and standard treatment, is 15 to 16 months. Fewer than 3% to 5% of patients survive longer than five years. Without treatment, survival is typically three months.
Clinical Trials for Cannabis Cancer Research
Cannabidiol (CBD) research is underway in cutting-edge clinical trials with their sites on finding alternate therapies for glioblastoma cancer treatment. Several studies have shown a potential anti-tumor role for cannabinoids by modulating cell signaling pathways, inhibiting the development of new blood cells, inducing the death of cancer cells, and overcoming chemotherapy resistance.
Biopharmaceutical research companies are committed to discovering and developing novel therapeutics from cannabinoid and are conducting clinical trials.
The primary objectives of interventional, clinical trials are to evaluate the overall response rates of cancer patients as assessed by standard criteria. The secondary objectives include measuring Time to Progression (TTP), measuring Progression-free Survival (PFS), and collecting patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO) regarding patient quality-of-life.
In Phase I trials, cannabinoids have been shown to enhance the uptake of chemotherapy into malignant cells without affecting normal cells. Cancer researchers seek to demonstrate that the combination of chemotherapy with CBD formulas will have a greater anti-tumor and anti-proliferative activity when compared to standard of care alone.
About Diverse Biotech, Inc.
Diverse Biotech Inc. is an innovative, clinical-stage biopharmaceutical research company, committed to discovering and developing novel therapeutics from its proprietary cannabinoid product platform.
For more information on Diverse Biotech or its Cannabinoid (CBD) clinical trials, use in the treatment of specific types of malignancies related to glioblastoma, myeloma, gastrointestinal, and breast cancer, when administered in conjunction with Standard of Care, please contact Diverse Biotech by phone at 407-776-9217 or visit the company’s headquarters at 805 S. Kirkman Rd, Suite 202, Orlando, Florida 32811.